New therapeutic options for invasive fungal diseases

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 4, 2001, Pages 301-308

  Rodriguez, Carina A ^a,b,c   Patrick, Christian C ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; BENZODIAZEPINE DERIVATIVE; CISAPRIDE; CLOTRIMAZOLE; CYCLOSPORIN; DIAZEPAM; FLUCONAZOLE; FLUCYTOSINE; GASTROINTESTINAL AGENT; GRISEOFULVIN; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; ITRACONAZOLE; MICONAZOLE; NYSTATIN; PHENYTOIN; RIFAMPICIN; STEROID; TERBINAFINE; UNINDEXED DRUG;

ANTIFUNGAL ACTIVITY; ARTHRALGIA; CHILL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HYPOTENSION; INFECTION RISK; MYALGIA; MYCOSIS; NEPHROTOXICITY; REVIEW; RISK FACTOR;

EID: 0034751683     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.26638     Document Type: Article

References (32)

1. Practice guidelines for diseases caused by Aspergillus
2. Invasive aspergillosis
3. Invasive aspergillosis in transplant recipients
4. Invasive aspergillosis infections in a pediatric hospital: A ten-year review
5. Practice guidelines for the treatment of Candidiasis
6. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer
7. Current and future antifungal therapy: New targets for antifungal agents
8. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
9. Antifungal drugs for systemic fungal infections
10. Pharmacokinetics of amphotericin B in infants and children
11. Introduction to antifungal drugs
12. Practice guidelines for the management of cryptococcal disease
13. Practice guidelines for the management of patients with blastomycosis
14. Practice guideline for the treatment of coccidioidomycpsis
15. Practice guidelines for the management of patients with sporotrichosis
16. Practice guidelines for the management of patients with histoplasmosis
17. Randomized, double-blinded clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
18. A randomized, double-blind comparative trial evaluating amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
19. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
20. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
21. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
22. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer
23. Safety and tolerability of fluconazole in children
24. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B (AMB), AMB lipid formulations, or azoles
25. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis
26. The exciting future of antifungal therapy
27. Synergistic effects of combination FK463 and amphotericin B: Enhanced efficacy in murine model of invasive pulmonary aspergillosis
28. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism
29. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents
30. Clinical relevance of antifungal resistance
31. Novelties in the field of anti-infective compounds in 1999